Table 5 Association of various characteristics with intolerance/toxicity-related ART discontinuation by Cox proportional hazard models in naive patients starting therapy between Jan 2011 and Feb 2017
Characteristic | Univariate analysis | Multivariable analysis | Multivariable analysis | |||
|---|---|---|---|---|---|---|
Model 1 | Model 2 | |||||
Hazard Ratio (95% Cl) | P-value | Hazard Ratio (95% Cl) | P-value | Hazard Ratio (95% Cl) | P-value | |
Age(years) | ||||||
≤ 45 | 1.0 | 1.0 | 1.0 | |||
> 45 | 1.5 (1.1–2.1) | 0.018 | 1.4 (1.0–2.0) | 0.036 | 1.4 (1.0–2.0) | 0.044 |
Sex | ||||||
Male | 1.0 | 1.0 | 1.0 | |||
Female | 1.6 (1.1–2.3) | 0.022 | 1.4 (1.0–2.1) | 0.089 | 1.3 (1.0–2.0) | 0.189 |
Transmission mode | ||||||
MSM/Bisexual | 1.0* | |||||
Heterosexual | 1.1 (0.8–1.6) | 0.519 | ||||
IVDU | 1.3 (0.2–2.0) | 0.960 | ||||
Other | 1.0 (0.3–3.3) | 0.964 | ||||
Unknown | 1.3 (0.7–2.4) | 0.341 | ||||
Viral load (copies/mm3) | ||||||
< 100.000 | 1.0 | |||||
≥ 100.000 | 1.0 (0.7–1.4) | 0.936 | ||||
AIDS diagnosis | ||||||
Category C or CD4 < 200 cells/mm3 | 1.3 (0.9–1.8) | 0.141 | ||||
Initiation era | ||||||
2011–2014 | 1.0 | 1.0 | 1.0 | |||
2015–2017 Feb | 0.7 (0.5–1.0) | 0.024 | 0.5 (0.4–0.9) | 0.001 | 0.5 (0.3–0.8) | <.0001 |
Class | ||||||
InSTI | 1.0* | 1.0* | ||||
NNRTI | 3.5 (2.1–5.7) | <.0001 | 5.8 (3.3–10.5) | <.0001 | ||
PI | 3.9 (2.5-6.3) | <.0001 | 5.6 (3.4–9.3) | <.0001 | ||
Regimen | ||||||
EVG/c/TDF/FTC | 1.0* | 1.0* | ||||
EFV/TDF/FTC | 4.0 (2.1–7.6) | <.0001 | 7.6 (3.7–15.3) | <.0001 | ||
LPV/r/TDF/FTC | 4.6 (2.5–8.6) | <.0001 | 7.5 (3.8–14.6) | <.0001 | ||
DTG/TDF/FTC | 1.3 (0.5–3.2) | 0.556 | 1.2 (0.5–3.0) | 0.667 | ||
DRV/r/TDF/FTC | 3.4 (1.6–7.3) | 0.001 | 4.4 (2.0–9.3) | <.0001 | ||
RAL/TDF/FTC | 1.8 (0.4–8.2) | 0.422 | 1.8 (0.4–8.2) | 0.430 | ||
LPV/r/ZDV/3TC | 11.3 (4.6–27.6) | <.0001 | 19.3 (7.4–50.6) | <.0001 | ||
EFV/ZDV/3TC | 4.5 (1.3–16.0) | 0.020 | 8.6 (2.3–32.4) | 0.001 | ||
Other | 1.0 (0.1–8.0) | 0971 | 1.2 (0.2-8.9) | 0890 | ||